Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
three
months ended in Dec. 2023,
RemeGen Co paidHK$0.0 Mil more to buy back shares than it received from issuing new shares.
It receivedHK$0.0 Mil from issuing more debt.
It paidHK$0.0 Mil more to buy back preferred shares than it received from issuing preferred shares.
It receivedHK$0.0 Mil from paying cash dividends to shareholders.
It receivedHK$0.0 Mil on other financial activities.
In all, RemeGen CospentHK$0.0 Mil on financial activities for the
three
months ended in Dec. 2023.
RemeGen Co Cash Flow from Financing Historical Data
The historical data trend for RemeGen Co's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
RemeGen Co's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$436.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RemeGen Co (HKSE:09995) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
RemeGen Co's issuance of stock for the
three
months ended in Dec. 2023 was HK$0.0 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
RemeGen Co's repurchase of stock for the
three
months ended in Dec. 2023 was HK$0.0 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
RemeGen Co's net issuance of debt for the
three
months ended in Dec. 2023 was HK$0.0 Mil.
RemeGen Co receivedHK$0.0 Mil from issuing more debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
RemeGen Co's net issuance of preferred for the
three
months ended in Dec. 2023 was HK$0.0 Mil.
RemeGen Co paidHK$0.0 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
RemeGen Co's cash flow for dividends for the
three
months ended in Dec. 2023 was HK$0.0 Mil.
RemeGen Co receivedHK$0.0 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
RemeGen Co's other financing for the
three
months ended in Dec. 2023 was HK$0.0 Mil.
RemeGen Co receivedHK$0.0 Mil on other financial activities.
RemeGen Co Cash Flow from Financing Related Terms
Thank you for viewing the detailed overview of RemeGen Co's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.
RemeGen was established in 2008 and listed on the Hong Kong Stock Exchange in 2020. It is a commercial stage biotech company focused on developing drugs to treat autoimmune disease, cancer, and ophthalmic disease for the China market and potentially the global market, as well. Its core assets are disitamab vedotin (RC48), a HER2-targeting antibody-drug conjugate (ADC) for treating HER2-expressing cancers, and telitacicept (RC18), a BLyS and APRIL targeting bispecific fusion protein for treating various B-cell mediated autoimmune diseases. These drugs received their first approvals in China in 2021 and are both covered on the National Reimbursement Drug List (NRDL).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:09995 has been successfully added to your 